NIDDK
|
Request for Information (RFI): Regarding Bioinformatics/Computational Needs for NIDDK Investigators Engaged in Diabetes, Endocrinology and Metabolic Diseases Research |
The National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) invites interested investigators to provide input on their needs for bioinformatics/computational support to advance R01-based research in Diabetes, Endocrinology and Metabolic Diseases. Responses to this RFI will be accepted through October 15, 2019. |
NIDDK
|
NIDDK Special Job Announcements 2019 |
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a component of the National Institutes of Health (NIH), are looking for applicants with significant research experience, who have a commitment to excellence, and the energy, enthusiasm, and innovative thinking necessary to lead dynamic and diverse programs. Applicants must be U.S. Citizens. |
NIDDK
|
Dr. William T. Cefalu to direct NIDDK Division of Diabetes, Endocrinology, and Metabolic Diseases |
NIDDK Director Dr. Griffin P. Rodgers announces Dr. William T. Cefalu as the new director of the Division of Diabetes, Endocrinology, and Metabolic Diseases at the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. An expert physician researcher, leader, and patient advocate, Dr. Cefalu will be responsible for setting scientific priorities within a large and diverse program of basic and clinical research. |
NIH
|
NIH HRHR program initiatives - Upcoming Webinars |
Notice of Pre-Application Webinars for the High-Risk, High-Reward Research Program's Pioneer (RFA-RM-19-005), New Innovator (RFA-RM-19-006), Transformative Research (RFA-RM-19-007), and Early Independence (RFA-RM-19-008) Awards. |
NIH
|
Drug delays type 1 diabetes in people at high risk |
A treatment affecting the immune system effectively slowed the progression to clinical type 1 diabetes in high risk individuals, according to findings from National Institutes of Health-funded research. The study is the first to show that clinical type 1 diabetes can be delayed by two or more years among people who are at high risk. |
NIH
|
Improvements in insulin release wane after treatment stops in adults with early type 2 diabetes |
A set of clinical trials examining youth and adults with type 2 diabetes or impaired glucose tolerance has found that disease progression in adults slowed during medical treatment but resumed after treatment stopped. Youth on the same treatment had markedly poorer outcomes with continued disease progression both during and after the treatment. |
NIH
|
NIH-funded trial finds vitamin D does not prevent type 2 diabetes in people at high risk |
Taking a daily vitamin D supplement does not prevent type 2 diabetes in adults at high risk, according to results from a study funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. The Vitamin D and Type 2 Diabetes (D2d) study enrolled 2,423 adults and was conducted at 22 sites across the United States. |
NIH
|
NIH study finds heavily processed foods cause overeating and weight gain |
People eating ultra-processed foods ate more calories and gained more weight than when they ate a minimally processed diet, according to results from a National Institutes of Health study. The difference occurred even though meals provided to the volunteers in both the ultra-processed and minimally processed diets had the same number of calories and macronutrients. |
NIH
|
Daily folic acid supplement may reduce risk of gestational diabetes |
Taking a folic acid supplement daily before pregnancy may reduce the risk of gestational, or pregnancy-related, diabetes, according to a study by researchers at the National Institutes of Health and other institutions. The findings appear in Diabetes Care. |
NIH
|
Watchful waiting reasonable for patients with diabetic macular edema and good vision |
People with good vision despite having center-involved diabetic macular edema can safely forego immediate treatment of their eye condition as long as they are closely monitored, and treatment begins promptly if vision worsens, according to clinical trial results. he findings are published online today in the Journal of the American Medical Association. |
NIH
|
Gout treatment may help prevent obesity-related type 2 diabetes, suggests small NIH study |
The drug colchicine, used to treat the arthritic condition gout, could potentially reduce complications accompanying metabolic syndrome, a combination of high blood pressure, high blood sugar and other conditions that increase the risk of heart disease and type 2 diabetes, according to researchers at the National Institutes of Health. Their study appears in Diabetes, Endocrinology, and Metabolism. |
NIH
|
KOMP Repository Mice and ES Cells Now at the MMRRC @ UC Davis |
The Mutant Mouse Resource and Research Center (MMRRC), the official National Institute of Health (NIH) repository of mouse models, is pleased to announce the availability of genetically-altered mice and embryonic stem (ES) cells made as part of the NIH Knockout Mouse Project (KOMP) and previously maintained in the KOMP Repository. |